A practical reference on actin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-24. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
=== Secret peace discussions, opposition to troop withdrawals === In June 1969, the former Defense Secretary Clark Clifford published an article in Foreign Affairs calling for the withdraw of 100,000 U.S. troops from Vietnam by the end of 1969 and all by the end of 1970. Influenced by Laird, Nixon announced the immediate withdraw of 25,000 U.S. troops from Vietnam, saying: "I would hope that we could beat Mr. Clifford's timetable". Kissinger was opposed to the withdrawal, which he predicted would mean the immediate collapse of South Vietnam. On 4 August 1969, Kissinger met secretly with Xuân Thủy at the Paris apartment of Jean Sainteny to discuss peace. Sainteny was a former French colonial official sympathetic to Vietnamese nationalism who had offered to serve as an honest broker. Kissinger had been hoping to see Tho rather than Thuy. Kissinger repeated the American offer of "mutual withdrawal" of U.S. and North Vietnamese forces from South Vietnam, which Thủy rejected, while Thủy demanded a new government in Saigon, which Kissinger rejected. Kissinger had a low opinion of North Vietnam, saying "I can't believe that a fourth-rate power like North Vietnam doesn't have a breaking point". Kissinger was opposed to the strategy of Vietnamization, expressing some doubt about the ability of the ARVN (Army of the Republic of Vietnam-i.e. the South Vietnamese Army) to hold the field, causing much tension with Defense Secretary Laird who was deeply committed to Vietnamization. In September 1969, Kissinger, in a memo, advised Nixon against "de-escalation", saying that keeping U.S.
=== Veterinary use === Veterinary clinics use cold laser devices to treat a wide variety of ailments, from arthritis to wounds, on dogs and cats. In spite of this, little research has been done on its effects. According to Brennen McKenzie, president of the Evidence-Based Veterinary Medicine Association, as of 2016 "research into cold laser in dogs and cats is sparse and generally low quality. Most studies are small and have minimal or uncertain controls for bias and error". He allowed that some studies show promising results, while concluding that current evidence is not sufficient to support routine clinical use.
Lactose, maltose and sucrose are disaccharides, also called "compound sugars". They share the formula C12H22O11. They are formed by the condensation of two monosaccharide molecules with the expulsion of a molecule of water.
Sources: en.wikipedia.org
== H == habitat – HACEK organism – halobacteria – haploid – Hardy–Weinberg principle – heart – Hela cell – helper T cell – Hepadnaviridae – hepatitis B – herbivore – heredity – hereditary disease – hermaphrodite – herpetology – Hershey–Chase experiment – heterochromatin – heterotroph – heterozygote – Hfr cell – hibernation – hierarchy of life – Hill reaction – His tag – histone – homeobox – homeostasis – homologous recombination – homology – homoplasy – homozygote – homunculus – horizontal gene transfer – hormone – host – household gene – human – Human Genome Project – humoral immunity – hybrid (biology) – hybridization – hydrolysis – hydrolytic enzyme – hygiene – hyperpolarization (biology)
== Later developments == In 1987 Pedro Cuatrecasas and Meir Wilchek were awarded the Wolf Prize in Medicine for the invention and development of affinity chromatography and its applications to biomedical sciences.
== Gel Preparation Methods == The process of gel formation involves finding a balance between the concentrations of the gelator and the solvent. When adding a gelator to the solvent, the mixture remains in liquid state. As the concentration of the gelator increases to a certain critical concentration (gelling point), gelation occurs through swelling to form the semi-solid gel. Further increasing the concentration of the gelator beyond the gelling point will increase gel viscosity. The exact gelling point varies depending on the properties of the gelator and the solvent, such as structure uniformity, molecular weight of the polymer, and flexibility of the polymer chain. Generally, gels are prepared by firstly dissolving the soluble excipients in the solvent. The solution is then mixed using a mechanical stirrer. After that, the gelator is added slowly to the stirred mixture in order to avoid aggregation. Then, the mixture is continuously stirred until the polymer dissolves and a gel gradually forms. The gel is allowed to settle for one to two days before the final consistency of the gel can be reached. The exact method of preparing gels depends on the properties of the formulation ingredients.
== Research == Liposomal medicine research for cancer therapy has increased over the years as an alternative to conventional cancer treatment. There is an interest in liposomal medicine because it features targeted drug delivery while mitigating the damage to healthy cells and tissues. One of the combination products under liposome therapy that is being researched for cancer therapy applications is immunoliposome therapy. Other research areas in liposome combination therapy include photodynamic therapy, photothermal agents, radiotherapy, and gas therapy agents. A immunoliposome therapy clinical study that was completed was conducted by the Swiss Group for Clinical Cancer Research from 2006 to 2009. The study was a phase II clinical trial that looked at the combination of commercially sold Doxorubicin with bevacizumab, a monoclonal antibody that blocks tumor growth. The therapy was used to treat patients with locally recurrent or metastatic breast cancer. Out of the 43 patients, 16 had grade 3 palmar-plantar erythrodysesthesia, one had grade 3 mucositis, and one severe cardiotoxicity, according to the study. As a result, the combination therapy demonstrated higher than anticipated toxicity while only having modest therapeutic effect. These results concluded that, although immunoliposome therapy has promise, there is still more research needed before translating into commercial products.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.